Clinical Trials
39 trialsLUNG-RESIST
University Hospital, Toulouse
RESAMEX
Groupe Francais De Pneumo-Cancerologie
Immune Signature Analysis of Disease Progression in Post Immunotherapy Lung Cancer Patients
Wake Forest University Health Sciences
Reducing the Incidence of Symptomatic Brain Metastases With MRI Surveillance
Wake Forest University Health Sciences
Paclitaxel Therapeutic Drug Monitoring in Cancer Patients
Wake Forest University Health Sciences
RICEPS-2
University Hospital, Tours
MetLung
Centre Oscar Lambret
ELEPHAS-04
Mayo Clinic
DuTOC
Dutch Society of Physicians for Pulmonology and Tuberculosis
Whole Body HER2 Quantification With 89Zr-Trastuzumab PET/CT to Asses Zr-trastuzumab Accumulation in HER2-mutated and HER2-overexpressing Metastatic Non-small Cell Lung Cancer
The Netherlands Cancer Institute
BREATHE
Nantes University Hospital
CLASSE-P1
Assistance Publique - Hôpitaux de Paris
LUNGDOC
University Hospital, Montpellier
DECIDE
Institut Claudius Regaud
MADMAS
Hospices Civils de Lyon
RESISTYR
Rennes University Hospital
CIRCUIT
University Hospital, Bordeaux
NEO-TAN
University Hospital, Montpellier
The Safety and Feasibility of Costal Bone Marrow Aspiration During Thoracic Surgery
Universitair Ziekenhuis Brussel
EGFR Lung Canc
Our Lady of the Lake Hospital
LUTON
Hospices Civils de Lyon
PROTEON
Centre Hospitalier Universitaire de Liege
Use Peripheral Blood Proteomics to Predict the Treatment Response and Toxicities in NSCLC Immunotherapy
University of Iowa
Exhaled Breath Analysis to Predict Risk of Symptomatic Pneumonitis
Wake Forest University Health Sciences
LUNGDIET
Assistance Publique - Hôpitaux de Paris
CINECI
University Hospital, Tours
PD-RAD
The Christie NHS Foundation Trust
Onco-PDL1s/B2M
University Hospital, Clermont-Ferrand
ADOPT
University of Dundee
Metabolic and Microbial Profiling of Lung Cancer
Wake Forest University Health Sciences
LUCID
Cambridge University Hospitals NHS Foundation Trust
NSCLC Heterogeneity in Early Stage Patients and Prediction of Relapse Using a Personalized "Liquid Biopsy"
Hellenic Oncology Research Group
LEMA
The Netherlands Cancer Institute
MSN
Gustave Roussy, Cancer Campus, Grand Paris
Rociletinib Genomic Landscape in Non-small Cell Lung Cancer (NSCLC)
Washington University School of Medicine
CIRCUBRONCH
Central Hospital, Nancy, France
Residual Hypermethylation in Early Stage Non-Small Cell Lung Cancer (NSCLC) As Part of Adjuvant Therapy and Preventive Strategy
University of Miami
Usefulness of Blood Biomarkers for Overall Survival in NSCLC
Maastricht Radiation Oncology
RESTORE-AIR
Royal Marsden NHS Foundation Trust